Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
Journal: The New England journal of medicine
Published: June 01, 2026
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.
Journal: Nature medicine
Published: June 24, 2024
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
Journal: British journal of cancer
Published: January 30, 2024
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer.
Journal: NPJ breast cancer
Published: November 15, 2021
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 06, 2021
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 06, 2021
Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice.
Journal: Current oncology (Toronto, Ont.)
Published: June 14, 2021
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 23, 2021
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Journal: Clinical breast cancer
Published: February 19, 2021
Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma.
Journal: Oncoimmunology
Published: October 26, 2020
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Journal: Lancet (London, England)
Published: August 05, 2020
Last Updated: 09/26/2026